You are here
- Home
- Rare lung diseases
Rare lung diseases
- Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, Kevin K Brown, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi-Saab, Marlies WijsenbeekBMJ Open Respiratory Research May 2019, 6 (1) e000422; DOI: 10.1136/bmjresp-2019-000422
- Veterans Specific Activity Questionnaire (VSAQ): a new and efficient method of assessing exercise capacity in patients with pulmonary arteriovenous malformationsFilip Gawecki, Jonathan Myers, Claire L. ShovlinBMJ Open Respiratory Research Mar 2019, 6 (1) e000351; DOI: 10.1136/bmjresp-2018-000351
- Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registryWim A Wuyts, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Natacha Gusbin, Christophe Compere, Sofie Maddens, Klaus-Uwe Kirchgaessler, Karen Bartley, Benjamin BondueBMJ Open Respiratory Research Nov 2018, 5 (1) e000331; DOI: 10.1136/bmjresp-2018-000331
- Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trialsJeffrey J Swigris, Hilary Wilson, Dirk Esser, Craig S Conoscenti, Wibke Stansen, Nancy Kline Leidy, Kevin K BrownBMJ Open Respiratory Research May 2018, 5 (1) e000278; DOI: 10.1136/bmjresp-2018-000278
- Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapyDaniel Franzen, Sarah R Haile, David C Kasper, Thomas P Mechtler, Andreas J Flammer, Pierre A Krayenbühl, Albina NowakBMJ Open Respiratory Research Apr 2018, 5 (1) e000277; DOI: 10.1136/bmjresp-2018-000277
- Long-term outcomes of patients with pulmonary arteriovenous malformations considered for lung transplantation, compared with similarly hypoxaemic cohortsClaire L Shovlin, Elisabetta Buscarini, J Michael B Hughes, David J Allison, James E JacksonBMJ Open Respiratory Research Oct 2017, 4 (1) e000198; DOI: 10.1136/bmjresp-2017-000198
- Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, Emmanuelle Clerisme-Beaty, Harold R Collard, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Florence Le Maulf, Luca Richeldi, Hendrik Schmidt, Simon Walsh, William Mezzanotte, Rozsa Schlenker-HercegBMJ Open Respiratory Research Sep 2017, 4 (1) e000212; DOI: 10.1136/bmjresp-2017-000212
- Clinical use of nintedanib in patients with idiopathic pulmonary fibrosisAmy Hajari Case, Peace JohnsonBMJ Open Respiratory Research Jun 2017, 4 (1) e000192; DOI: 10.1136/bmjresp-2017-000192
- Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registryEmily C O'Brien, Michael T Durheim, Victoria Gamerman, Sandy Garfinkel, Kevin J Anstrom, Scott M Palmer, Craig S ConoscentiBMJ Open Respiratory Research Jan 2016, 3 (1) e000108; DOI: 10.1136/bmjresp-2015-000108
- Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacyGiacomo Sgalla, Stefania Cerri, Roberto Ferrari, Maria Pia Ricchieri, Stefano Poletti, Margherita Ori, Martina Garuti, Gloria Montanari, Fabrizio Luppi, Kyriakoula Petropulacos, Luca RicheldiBMJ Open Respiratory Research Mar 2015, 2 (1) e000065; DOI: 10.1136/bmjresp-2014-000065
Pages
- BMJ Open Respiratory Research
- Cough (3)
- Critical care (8)
- Cystic fibrosis (3)
- Lung cancer (9)
- Sleep (2)
- Thoracic surgery (1)
- Tuberculosis (2)